Vor Biopharma (NYSE:VOR) Earns “Outperform” Rating from Wedbush

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report issued on Tuesday, Benzinga reports. They presently have a $11.00 price target on the stock. Wedbush’s price target suggests a potential upside of 488.24% from the stock’s previous close.

A number of other research firms also recently issued reports on VOR. Stifel Nicolaus lowered their price objective on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, March 21st. JMP Securities restated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Friday, March 22nd. HC Wainwright reissued a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a report on Thursday, March 21st. Finally, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective (down previously from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vor Biopharma currently has a consensus rating of “Buy” and an average target price of $13.50.

Vor Biopharma Stock Up 2.7 %

Shares of VOR traded up $0.05 during midday trading on Tuesday, hitting $1.87. The company had a trading volume of 132,075 shares, compared to its average volume of 292,526. Vor Biopharma has a 52 week low of $1.62 and a 52 week high of $5.70. The stock has a market cap of $127.57 million, a price-to-earnings ratio of -1.07 and a beta of -0.36. The company’s 50 day moving average price is $2.04 and its 200 day moving average price is $2.11.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.10. Equities analysts anticipate that Vor Biopharma will post -1.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

An institutional investor recently bought a new position in Vor Biopharma stock. SG Americas Securities LLC bought a new stake in shares of Vor Biopharma Inc. (NYSE:VOR) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 17,258 shares of the company’s stock, valued at approximately $37,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.